Chengdu Olymvax Biopharmaceuticals Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 232.27 million compared to CNY 168.29 million a year ago. Revenue was CNY 232.71 million compared to CNY 169.12 million a year ago.

Net income was CNY 31.04 million compared to CNY 42.35 million a year ago. Basic earnings per share from continuing operations was CNY 0.0766 compared to CNY 0.1161 a year ago. Diluted earnings per share from continuing operations was CNY 0.0766 compared to CNY 0.1161 a year ago.